A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

You might be able to join this study if you're between 16 and 75 years old and have been involved in a previous Upadacitinib study for ulcerative colitis. This includes if your symptoms didn't fully improve after the first part of that study, or if your symptoms returned after getting better. You could also be eligible if you successfully finished the previous Upadacitinib study.

To be considered, female participants must not be pregnant, trying to get pregnant, or breastfeeding, and they need to use effective contraception. Generally, you should also be in good overall health, as decided by the study doctor based on your previous medical checks from the earlier study.

You would not be able to join if the study doctor thinks you're not suitable for any reason, or if you've had a bad reaction to Upadacitinib or its ingredients in the past. People with active infections, including untreated tuberculosis, would also not be able to take part until the infection is successfully treated.

If you join this study, you will continue to receive either Upadacitinib or a placebo (a dummy medicine with no active drug) if you were in the previous study's maintenance phase, or only Upadacitinib if you successfully completed the full previous study. You'll have regular visits to the clinic where the study team will monitor your health, check for any side effects, and see how your ulcerative colitis is responding to the treatment. This will involve physical examinations, blood tests, and possibly other assessments like stool samples or questionnaires about your symptoms. The exact number and frequency of visits will be explained by the study team, but they are designed to closely monitor your health and the effects of the medicine over a longer period.